<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In an effort to develop more effective therapy for patients with refractory or relapsed <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), we investigated the efficacy of a combination chemotherapy consisting of <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and topotecan </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-seven patients were treated: four with primary refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, nine with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in first relapse, four with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in second relapse, and 10 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received as salvage therapy a single course of <z:chebi fb="0" ids="42068">idarubicin</z:chebi> 12 mg/m(2) IV bolus on days 1-3, <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 1 g/m(2) over two hours q 12 hr on days 1-5, and topotecan 1.25 mg/m(2) over 24 hr on days 1-5 </plain></SENT>
<SENT sid="3" pm="."><plain>Median age was 42 years (range 17-65 years) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were evaluable for response: 14 (51.9%) achieved complete remission, 10 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (59%) and four with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (40%), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Thirteen <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients (excluding four relapsed after autologous stem cell transplantation) were grouped into four categories to stratify the probability of achieving complete remission (CR): group 1, first CR duration &gt; or = 2 years and receiving first salvage treatment (S1); group 2, first CR duration 1-2 years and receiving S1; group 3, first CR duration 0-1 years and receiving S1; and group 4, first CR duration 0-1 years and receiving S2, S3, or S4 after failing S1 </plain></SENT>
<SENT sid="6" pm="."><plain>The response rate of each group was as follows: group 1, one of two (50%); group 2, one of one (100%); group 3, four of four (100%); group 4, two of six (33.3%) </plain></SENT>
<SENT sid="7" pm="."><plain>The median remission duration and survival of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were six and 12 months, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Median duration of survival in 10 MDS patients was 15 months, and <z:hpo ids='HP_0000001'>all</z:hpo> four <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients achieving a CR maintained continuous CR with a median follow-up of 11 months </plain></SENT>
<SENT sid="9" pm="."><plain>Severe <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> was observed in <z:hpo ids='HP_0000001'>all</z:hpo> patients, resulting in <z:hpo ids='HP_0001945'>fever</z:hpo> or documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in 89% of patients </plain></SENT>
<SENT sid="10" pm="."><plain>Median time to recovery of neutrophils &gt; or =0.5 x 10(9)/l was 22 days (11-34) and for platelets &gt; 20 x 10(9)/l 35 days (11-58) </plain></SENT>
<SENT sid="11" pm="."><plain>Reversible grade 3-4 toxicities included <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (two patients) and mucositis (seven patients) </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that combination chemotherapy with intermediate dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, and topotecan has significant antileukemic activity and acceptable toxicity in salvage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>